Serotiny

Serotiny is a pioneering biotechnology firm based in South San Francisco, California, dedicated to engineering the next generation of cell and gene therapies. The company specializes in inventing genes that encode therapeutic multi-domain proteins (tMDPs), which are distinct from traditional therapeutic proteins like antibodies or biologics. These tMDPs are delivered as genetic material and expressed within human cells, providing new functionalities often unrelated to protein structure. Serotiny’s approach involves versioning massive libraries of genes tailored for specific therapeutic goals, utilizing software, DNA-synthesis, and sequencing technologies to manage biological complexity. The company’s innovative use of software aids in the rational design of tMDPs, which poses unique challenges compared to other biologics. Serotiny also conducts high-throughput assays in mammalian cells and designs experiments that integrate machine learning and computational biology. Notably, Serotiny has entered into several strategic collaborations, including with Janssen for optimizing Chimeric Antigen Receptors Signaling Domains, with Tessera Therapeutics for engineering programmable Gene Writer proteins, and with Twist Biopharma to create custom DNA libraries. The company’s headquarters are located at 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA 94080, and can be contacted via email at info@serotiny.com.